Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19

A clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than remdesivir alone for treating adults hospitalized with the disease. The trial also found that the safety of this experimental treatment may vary depending on whether a person naturally generates SARS-CoV-2-neutralizing antibodies before receiving it. The results of the multinational Phase 3 trial were published today in the journal The Lancet.

source https://medicalxpress.com/news/2022-01-hyperimmune-intravenous-immunoglobulin-outcomes-adults.html